InvestSMART

Starpharma Holdings Limited (ASX: SPL) - Announcements

Current share price for SPL : $0.790 0.005 (0.63%)+

ASX company news and announcements for Starpharma Holdings Limited (SPL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Starpharma Holdings Limited (SPL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Starpharma Holdings Limited (SPL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Starpharma Holdings Limited (SPL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$333 DEP irinotecan clinical data presented at AACR meeting 16 Oct 2023 10:02AM $0.140 $0.790 risen by 464.29%
$333 Ceasing to be a substantial holder 16 Oct 2023 8:07AM $0.140 $0.790 risen by 464.29%
$333 Application for quotation of securities - SPL 9 Oct 2023 2:05PM $0.135 $0.790 risen by 485.19%
$333 Change in Director's Interest Notice - J Fairley 6 Oct 2023 2:16PM $0.140 $0.790 risen by 464.29%
$333 Notification of cessation of securities - SPL 6 Oct 2023 2:10PM $0.140 $0.790 risen by 464.29%
$333 2023 Annual General Meeting Date 2 Oct 2023 9:06AM $0.165 $0.790 risen by 378.79%
$333 Ceasing to be a substantial holder 29 Sep 2023 5:24PM $0.165 $0.790 risen by 378.79%
$333 DEP irinotecan combination data presentation 27 Sep 2023 8:58AM $0.160 $0.790 risen by 393.75%
$333 VIRALEZ UK COVID-19 Clinical Study Completes Recruitment 25 Sep 2023 9:55AM $0.150 $0.790 risen by 426.67%
$333 Change in substantial holding 20 Sep 2023 2:31PM $0.155 $0.790 risen by 409.68%
$333 Positive DEP irinotecan clinical results presentation 13 Sep 2023 9:46AM $0.130 $0.790 risen by 507.69%
$333 Change in substantial holding 12 Sep 2023 5:10PM $0.130 $0.790 risen by 507.69%
$333 Company Secretary Appointment/Resignation 28 Aug 2023 9:17AM $0.140 $0.790 risen by 464.29%
$333 Corporate Governance Statement 25 Aug 2023 4:46PM $0.140 $0.790 risen by 464.29%
$333 Appendix 4G - Corporate Governance Statement 24 Aug 2023 9:38AM $0.145 $0.790 risen by 444.83%
$333 App 4E/Annual Report to shareholders 24 Aug 2023 9:37AM $0.145 $0.790 risen by 444.83%
$333 Change in substantial holding 17 Aug 2023 6:09PM $0.160 $0.790 risen by 393.75%
$333 Change in substantial holding 17 Aug 2023 4:20PM $0.160 $0.790 risen by 393.75%
$333 Change in substantial holding 15 Aug 2023 4:42PM $0.170 $0.790 risen by 364.71%
$333 SPL to receive $6.5M from Mundipharma and VivaGel BV rights 14 Aug 2023 8:15AM $0.150 $0.790 risen by 426.67%
$333 Change in substantial holding 2 Aug 2023 8:26AM $0.195 $0.790 risen by 305.13%
$333 Partnered Program Update 31 Jul 2023 10:07AM $0.325 $0.790 risen by 143.08%
$333 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jul 2023 9:53AM $0.325 $0.790 risen by 143.08%
$333 Trading Halt 28 Jul 2023 9:51AM $0.325 $0.790 risen by 143.08%
$333 Pause in Trading 28 Jul 2023 9:45AM $0.325 $0.790 risen by 143.08%

151 - 175 of 866 results

Page 7 of 35

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.